GlassScriptPhysician profile
Kevin P Ryan
NPI 1033137641
$4,287.25
in general payments reported to CMS, 2019-2025
26 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,531 · 2020: $616 · 2021: $617 · 2022: $569 · 2023: $617 · 2024: $192 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,701.08 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Ingevity Mri, Emblem Mri S-Icd |
| Actelion Pharmaceuticals US, INC. | $488.68 | 2019-2025 | Opsumit, Opsynvi |
| Novartis Pharmaceuticals Corporation | $244.28 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $219.75 | 2019-2022 | |
| Medtronic Vascular, INC. | $202.54 | 2019 | |
| Inari Medical, INC. | $173.90 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic, INC. | $163.75 | 2021-2025 | Abre, Telescope, Micra |
| E.R. Squibb & Sons, L.L.C. | $152.59 | 2022-2024 | Eliquis, Camzyos |
| Amgen INC. | $119.91 | 2019-2023 | Repatha |
| Abbott Laboratories | $116.53 | 2020-2021 | |
| Hitachi Healthcare Americas Corp. | $114.33 | 2020 | |
| Novo Nordisk INC | $112.72 | 2024-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $102.60 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $68.14 | 2022-2025 | Lifevest |
| Esperion Therapeutics, INC. | $66.38 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $48.65 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Pfizer INC. | $40.45 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $21.35 | 2023 | Venovo |
| Edwards Lifesciences Corporation | $21.25 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $20.67 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $20.53 | 2021 | |
| United Therapeutics Corporation | $16.57 | 2020 | |
| Philips North America LLC | $13.66 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $12.92 | 2019 | |
| Siemens Medical Solutions USA, INC. | $12.43 | 2020 | |
| Elutia, INC. | $11.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.